查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715608

自體免疫疾病藥物市場：2025-2030 年全球預測（按治療類型、疾病類型、給藥途徑、治療用途和最終用戶）

Autoimmune Disease Therapeutics Market by Therapeutic Types, Disease Type, Route of Administration, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計2024年自體免疫疾病治療市場規模將達2,146.5億美元，2025年將達2,311.5億美元，複合年成長率為7.76%，2030年將達3,362.6億美元。

主要市場統計數據
基準年2024年 2146.5億美元
預計2025年 2311.5億美元
預測年份 2030 3362.6億美元
複合年成長率（%） 7.76%

自體免疫疾病藥物正處於創新科學和現實世界患者影響的交叉點。由於個人化醫療和標靶治療正在迅速改變治療方法，本報告全面概況了該領域的現狀和新興趨勢。在強大的資料集、臨床見解和市場動態的支持下，分析強調了對自體免疫疾病的理解和管理的重大進展。

在生物製藥和小分子突破的推動下，治療領域正在不斷發展，人們對免疫調節和免疫抑制藥物有著濃厚的興趣。相關人員現在可以獲得針對特定疾病特徵和患者需求的多種治療方案。這種演變不僅最佳化了臨床結果，而且還在主要市場相關人員之間培養了競爭性創新環境。

深入研究這個市場的複雜性可以揭示研究進步、監管變化和以患者為中心的方法之間的相互作用。我們的研究彌合了臨床效果和商業性可行性之間的差距，最終為決策者提供了他們所需的洞察力，以應對重新定義的治療模式。

改變自體免疫疾病藥物市場

近年來，發生了一些變革，重新定義了自體免疫疾病治療的模式。分子生物學研究的突破，加上開創性的臨床試驗，正在徹底改變全球臨床醫生可用的治療選擇。基因治療的進步和單株抗體的演化提高了針對自體免疫疾病潛在機制的精確度。

監管機構正在調整其框架以適應創新治療方法，從而加快核准流程，同時不影響安全性和有效性標準。這種轉變加速了融合蛋白和細胞激素抑制劑融入主流治療方法的速度。此外，對個人化醫療的日益重視正在鼓勵行業領導者接受患者特定數據，從而刺激創新生技藥品和小分子的市場化。

這些變化的影響是多方面的。臨床研究人員和製藥公司之間加強合作不僅促進了新療法的開發，而且重塑了醫療保健提供者和患者之間的關係。改進的診斷技術和病患監測現在是治療策略不可或缺的一部分，有助於早期療育和動態治療調整。因此，市場正在經歷一個以治療結果改善和更加重視以患者為中心的護理為特徵的時代。

關鍵環節綜合分析

在這種更廣泛的分析中，細分在理解市場複雜性和釋放機會方面發揮關鍵作用。市場分析基於治療類型，提供從抗高血糖藥物到生物製藥、細胞激素抑制劑、免疫調節劑和免疫抑制劑等領域的見解。此類別的進一步分析包括非類固醇消炎劑、磷酸二酯酶抑制劑和小分子化合物。其中，生物製藥分為融合蛋白、基因治療藥物、單株抗體等；小分子藥物分為皮質類固醇、JAK抑制劑等。

疾病細分檢查發炎性腸道疾病腸道疾病、紅斑性狼瘡、多發性硬化症、乾癬、類風濕性關節炎和第 1 型糖尿病等疾病。這種細分提供了對每種疾病如何回應各種治療性介入的細緻理解，從而導致差異化的護理途徑。給藥途徑也是一個重要的細分軸，分為注射給藥和口服給藥。特別強調注射劑，進一步細分為肌肉注射、靜脈注射和皮下注射。

進一步的細分考慮了治療應用，其中改變疾病進展、調節免疫系統、控制疼痛和減少發炎成為關鍵類別。最終用戶細分重點是門診手術中心、醫院和研究機構，以進一步明確市場動態。這些細分參數結合起來提供了對市場需求的多層次理解，使相關人員能夠客製化他們的策略方法，以適應不同的收益來源和技術進步。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 醫療保健專業人員和患者對自體免疫疾病的認知和理解日益加深
      • 擴大新興市場的醫療基礎設施和可近性拓寬了治療前景
      • 自體免疫疾病的盛行率在世界各地不斷上升，因此需要有效的治療方法
    • 限制因素
      • 生物製劑和新治療方法高成本
    • 機會
      • 利用精準醫療技術進步加強個人化治療
      • 整合數位健康平台，提供全面的患者照護和遠端監控
    • 任務
      • 新治療方法的核准過程漫長而複雜
  • 市場區隔分析
    • 治療類型：針對全身性發炎訊號分子的細胞激素抑制劑療法的需求日益增加。
    • 最終用戶：醫院擴大使用自體免疫疾病治療來管理慢性和急性自體免疫疾病
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章自體免疫疾病藥物市場（依治療類型）

  • 抗高血糖藥物
  • 生物製藥
    • 融合蛋白
    • 基因治療
    • 單株抗體
  • 細胞激素抑制劑
  • 免疫調節藥物
  • 免疫抑制劑
  • 非類固醇消炎劑（NSAID）
  • 磷酸二酯酶抑制劑
  • 小分子
    • 皮質類固醇
    • JAK抑制劑

第7章自體免疫疾病藥物市場（依疾病類型）

  • 發炎性腸道疾病
  • 紅斑狼瘡
  • 多發性硬化症
  • 乾癬
  • 類風濕性關節炎
  • 1型糖尿病

第8章自體免疫疾病藥物市場（依給藥途徑）

  • 注射
    • 肌肉注射
    • 靜脈
    • 皮下
  • 口服

第9章自體免疫疾病藥物市場（依治療應用）

  • 疾病進展的變化
  • 免疫系統調節
  • 疼痛管理
  • 減少炎症

第 10 章自體免疫疾病治療市場（按最終用戶）

  • 門診手術中心
  • 醫院
  • 研究組織

第 11 章：美洲自體免疫疾病藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太地區自體免疫疾病藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13.歐洲、中東和非洲自體免疫疾病藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abbott Laboratories
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Beckman Coulter, Inc.
  • Bio-Rad Laboratories, Inc.
  • BioAgilytix Labs, LLC
  • bioMerieux SA
  • Bristol-Myers Squibb Company
  • Eli Lilly and Company
  • Exagen, Inc.
  • F. Hoffmann-La Roche Ltd.
  • GlaxoSmithKline PLC
  • Johnson & Johnson Services, Inc.
  • Lupin Limited
  • Merck & Co., Inc.
  • Novartis AG
  • Pfizer, Inc.
  • Sanofi SA
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech PLC
  • UCB SA
  • Werfen SA
Product Code: MRR-030C42D3EDB7

The Autoimmune Disease Therapeutics Market was valued at USD 214.65 billion in 2024 and is projected to grow to USD 231.15 billion in 2025, with a CAGR of 7.76%, reaching USD 336.26 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 214.65 billion
Estimated Year [2025] USD 231.15 billion
Forecast Year [2030] USD 336.26 billion
CAGR (%) 7.76%

Autoimmune disease therapeutics stand at the intersection of innovative science and real-world patient impact. In an era where personalized medicine and targeted therapies are rapidly transforming treatment approaches, this report provides a comprehensive overview of the current landscape and emerging trends in the field. Drawing from robust datasets, clinical insights, and market dynamics, our analysis highlights the significant strides made in understanding and managing autoimmune disorders.

The therapeutic arena is evolving, driven by breakthroughs in biologics and small molecules, alongside a keen interest in immunomodulators and immunosuppressants. Stakeholders now have access to an expansive array of treatment options tailored to specific disease profiles and patient needs. This evolution not only optimizes clinical outcomes but also fosters an environment of competitive innovation among key market players.

As we delve deeper into the complexities of this market, the interplay of research advancements, regulatory shifts, and patient-centric approaches becomes evident. Our exploration bridges the gap between clinical efficacy and commercial viability, ultimately providing decision-makers with the insights needed to navigate a redefined therapeutic landscape.

Transformative Shifts in Autoimmune Disease Therapeutics Landscape

Recent years have witnessed transformative shifts that have redefined the autoimmune disease therapeutics landscape. Breakthroughs in molecular research, coupled with pioneering clinical trials, are remodeling the therapeutic arsenal available to clinicians worldwide. Advances in gene therapy and the evolution of monoclonal antibodies have introduced precision when targeting the underlying mechanisms of autoimmune conditions.

Regulatory bodies are adjusting frameworks to accommodate innovative treatment modalities, enabling faster approval processes without compromising safety and efficacy standards. This shift has allowed for the accelerated integration of fusion proteins and cytokine inhibitors into mainstream treatment regimens. Additionally, emphasis on personalized medicine is pushing industry leaders to embrace patient-specific data, fueling infusion of innovative biologics and small molecules into the market.

The impact of these changes is multifaceted. Enhanced collaboration between clinical researchers and pharmaceutical companies has not only led to the development of novel therapeutic agents but has also restructured the relationship between healthcare providers and patients. Improved diagnostic techniques and patient monitoring are now integral parts of treatment strategies, facilitating early intervention and dynamic treatment adjustments. As a result, the market is witnessing an era marked by both improved therapeutic outcomes and a heightened focus on patient-centric care.

Key Segmentation Insights: A Comprehensive Analysis

In this extensive analysis, segmentation plays a vital role in understanding market intricacies and unlocking opportunities. The market is dissected based on therapeutic types, providing insights that range from antihyperglycemics to biologics, cytokine inhibitors, immunomodulators, and immunosuppressants. Further analysis in this category delves into nonsteroidal anti-inflammatory drugs, phosphodiesterase inhibitors, and small molecules. Among these, biologics are scrutinized further into fusion proteins, gene therapy, and monoclonal antibodies, while small molecules are examined via the lens of corticosteroids and JAK inhibitors.

Disease-specific segmentation examines conditions including inflammatory bowel disease, lupus erythematosus, multiple sclerosis, psoriasis, rheumatoid arthritis, and type 1 diabetes. This breakdown provides a nuanced understanding of how each disorder responds to varying therapeutic interventions, leading to differentiated care pathways. The route of administration also forms a key segmentation axis, categorized into injectable and oral formats. Special emphasis is placed on injectable modes, which are further refined through intramuscular, intravenous, and subcutaneous methods.

Further segmentation examines therapeutic applications, where disease progression alteration, immune system modulation, pain management, and reduction of inflammation emerge as critical categories. The end-user segmentation further delineates market dynamics by focusing on ambulatory surgical centers, hospitals, and research institutes. Combined, these segmentation parameters offer a layered understanding of market demand, enabling stakeholders to customize their strategic approaches in line with diverse revenue streams and technological advancements.

Based on Therapeutic Types, market is studied across Antihyperglycemics, Biologics, Cytokine Inhibitors, Immunomodulators, Immunosuppressants, Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Phosphodiesterase Inhibitors, and Small Molecules. The Biologics is further studied across Fusion Proteins, Gene Therapy, and Monoclonal Antibodies. The Small Molecules is further studied across Corticosteroids and JAK Inhibitors.

Based on Disease Type, market is studied across Inflammatory Bowel Disease, Lupus Erythematosus, Multiple Sclerosis, Psoriasis, Rheumatoid Arthritis, and Type 1 Diabetes.

Based on Route of Administration, market is studied across Injectable and Oral. The Injectable is further studied across Intramuscular, Intravenous, and Subcutaneous.

Based on Therapeutic Application, market is studied across Disease Progression Alteration, Immune System Modulation, Pain Management, and Reduction of Inflammation.

Based on End-User, market is studied across Ambulatory Surgical Centers, Hospitals, and Research Institutes.

Regional Dynamics in the Autoimmune Disease Therapeutics Market

Global market dynamics are profoundly influenced by regional nuances, where differences in healthcare infrastructure, regulatory environments, and economic conditions create unique opportunities and challenges. In the Americas, advanced healthcare systems and strong R&D capabilities have fostered an innovative therapeutic environment. Market activities in this region are underpinned by robust investment in clinical trials and a proactive regulatory framework that encourages rapid adoption of innovative therapies.

Meanwhile, in Europe, the Middle East & Africa, a blend of mature markets and emerging economies provides fertile ground for both incremental and breakthrough innovations. The intricate balance between established treatment protocols and the need for next-generation therapeutics catalyzes targeted research and strategic collaborations.

Asia-Pacific, on the other hand, emerges as a rapidly growing hub marked by expanding healthcare access and significant investment in biotech research. These regions benefit from a dynamic market landscape that favors technological adoption and scale-driven growth. Each geography, with its distinct market drivers and challenges, enriches the overall narrative of the autoimmune disease therapeutics landscape, offering stakeholders a spectrum of regional insights to tailor their strategic initiatives.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Leading Companies Shaping the Industry Landscape

Dominant market players continue to set high standards in research and development, innovation, and market penetration. Prestigious names such as Abbott Laboratories and AbbVie Inc. lead the charge with their extensive portfolios and robust pipeline of therapeutic solutions. Industry giants like Amgen Inc. and AstraZeneca PLC are instrumental in driving forward clinical innovation, backed by strong academic and research partnerships.

The presence of companies such as Beckman Coulter, Inc. and Bio-Rad Laboratories, Inc. not only underscores the commitment to technological advancement but also highlights the diverse approaches to diagnostics and treatment efficacy. Emerging industry leaders, including BioAgilytix Labs, LLC and bioMerieux S.A., continue to push the boundaries of what is possible, integrating advanced biotechnological methodologies into routine clinical practice.

Bristol-Myers Squibb Company and Eli Lilly and Company have set formidable benchmarks in developing next-generation treatments that address the complex biologies of autoimmune diseases. Equally notable, Exagen, Inc. alongside F. Hoffmann-La Roche Ltd., are recognized for their contributions to groundbreaking research and sophisticated test methodologies. Global leaders such as GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., and Lupin Limited further drive market dynamics through sustained investment in innovation. The strategic moves of Merck & Co., Inc., Novartis AG, Pfizer, Inc., and Sanofi S.A. continue to influence competitive positioning and market evolution. In addition, companies like Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, UCB S.A., and Werfen S.A. round out the industry landscape, collectively forging pathways toward enhanced therapeutic efficacy and improved patient outcomes.

The report delves into recent significant developments in the Autoimmune Disease Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, AbbVie Inc., Amgen Inc., AstraZeneca PLC, Beckman Coulter, Inc., Bio-Rad Laboratories, Inc., BioAgilytix Labs, LLC, bioMerieux S.A., Bristol-Myers Squibb Company, Eli Lilly and Company, Exagen, Inc., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Johnson & Johnson Services, Inc., Lupin Limited, Merck & Co., Inc., Novartis AG, Pfizer, Inc., Sanofi S.A., Siemens Healthineers AG, Thermo Fisher Scientific Inc., Trinity Biotech PLC, UCB S.A., and Werfen S.A.. Actionable Recommendations for Industry Leaders

Industry leaders must focus on dynamic strategies that not only capitalize on current trends but also anticipate future innovations in autoimmune disease therapeutics. Firstly, it is imperative to invest heavily in research and clinical trials that explore novel mechanisms of action, particularly within the rapidly evolving biologics and small molecules sectors. Building strategic alliances with leading academic institutions and biotech firms could enhance collaborative research and expand market reach.

Leaders should also consider diversifying their portfolios to mitigate risks associated with market volatility and regulatory changes. Embracing a multi-pronged approach that involves targeted investments in precision medicine, digital health integration, and adaptive clinical trial designs will be critical. Moreover, a forward-thinking approach to market segmentation, taking into account diverse therapeutic types, disease indications, and routes of administration, can provide a competitive edge.

Investing in state-of-the-art diagnostic technologies and fostering communication channels between clinicians and researchers can lead to more informed decision-making and better patient outcomes. Furthermore, leaders are encouraged to monitor regulatory developments across key geographical regions to adapt strategies in real-time, ensuring they remain agile in the face of shifting policies. These recommendations serve as a roadmap for stakeholders to optimize both clinical and commercial success in a highly competitive marketplace.

Conclusion: Strategic Reflections for Future Progress

In closing, the journey through the autoimmune disease therapeutics market reveals a landscape marked by rapid innovation, diversified therapeutic strategies, and comprehensive regional dynamics. This competitive field continues to witness remarkable advancements that are redefining traditional paradigms of treatment and patient care. With the convergence of sophisticated biotechnologies and evolving regulatory frameworks, industry stakeholders now face an unprecedented opportunity to impact health outcomes in profound ways.

The analysis presented here underscores the importance of strategic thinking, robust segmentation, and regional-specific insights in driving forward both research and commercial success. As entities position themselves for future growth, they must harness emerging technologies and collaborative networks to remain at the forefront of innovation. Ultimately, the dynamic interplay between clinical research and market trends serves as the linchpin for transformative progress in autoimmune disease therapeutics.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness and understanding of autoimmune diseases among healthcare professionals and patients
      • 5.1.1.2. Expanding healthcare infrastructure and access in emerging markets broadening the treatment landscape
      • 5.1.1.3. Increasing prevalence of autoimmune diseases worldwide necessitating effective treatment solutions
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of biologic therapies and novel treatments
    • 5.1.3. Opportunities
      • 5.1.3.1. Leveraging technological advancements in precision medicine to enhance personalized treatment
      • 5.1.3.2. Integrating digital health platforms to provide holistic patient care and remote monitoring
    • 5.1.4. Challenges
      • 5.1.4.1. Complex and lengthy approval process for new therapies
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Therapeutic Types: Rising need for cytokine inhibitors therapies to target signaling molecules involved in systemic inflammation
    • 5.2.2. End-User: Growing utilization of autoimmune disease therapies in hospitals for managing chronic and acute autoimmune conditions
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Autoimmune Disease Therapeutics Market, by Therapeutic Types

  • 6.1. Introduction
  • 6.2. Antihyperglycemics
  • 6.3. Biologics
    • 6.3.1. Fusion Proteins
    • 6.3.2. Gene Therapy
    • 6.3.3. Monoclonal Antibodies
  • 6.4. Cytokine Inhibitors
  • 6.5. Immunomodulators
  • 6.6. Immunosuppressants
  • 6.7. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
  • 6.8. Phosphodiesterase Inhibitors
  • 6.9. Small Molecules
    • 6.9.1. Corticosteroids
    • 6.9.2. JAK Inhibitors

7. Autoimmune Disease Therapeutics Market, by Disease Type

  • 7.1. Introduction
  • 7.2. Inflammatory Bowel Disease
  • 7.3. Lupus Erythematosus
  • 7.4. Multiple Sclerosis
  • 7.5. Psoriasis
  • 7.6. Rheumatoid Arthritis
  • 7.7. Type 1 Diabetes

8. Autoimmune Disease Therapeutics Market, by Route of Administration

  • 8.1. Introduction
  • 8.2. Injectable
    • 8.2.1. Intramuscular
    • 8.2.2. Intravenous
    • 8.2.3. Subcutaneous
  • 8.3. Oral

9. Autoimmune Disease Therapeutics Market, by Therapeutic Application

  • 9.1. Introduction
  • 9.2. Disease Progression Alteration
  • 9.3. Immune System Modulation
  • 9.4. Pain Management
  • 9.5. Reduction of Inflammation

10. Autoimmune Disease Therapeutics Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Hospitals
  • 10.4. Research Institutes

11. Americas Autoimmune Disease Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Autoimmune Disease Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Autoimmune Disease Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. UCB announces extended FDA approvals for BIMZELX for the treatment of inflammatory autoimmune diseases
    • 14.3.2. Lupin launches Rymti biosimilar Etanercept in Canada
    • 14.3.3. AbbVie enhances inflammatory disease portfolio by acquiring Landos Biopharma to accelerate NX-13 development
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abbott Laboratories
  • 2. AbbVie Inc.
  • 3. Amgen Inc.
  • 4. AstraZeneca PLC
  • 5. Beckman Coulter, Inc.
  • 6. Bio-Rad Laboratories, Inc.
  • 7. BioAgilytix Labs, LLC
  • 8. bioMerieux S.A.
  • 9. Bristol-Myers Squibb Company
  • 10. Eli Lilly and Company
  • 11. Exagen, Inc.
  • 12. F. Hoffmann-La Roche Ltd.
  • 13. GlaxoSmithKline PLC
  • 14. Johnson & Johnson Services, Inc.
  • 15. Lupin Limited
  • 16. Merck & Co., Inc.
  • 17. Novartis AG
  • 18. Pfizer, Inc.
  • 19. Sanofi S.A.
  • 20. Siemens Healthineers AG
  • 21. Thermo Fisher Scientific Inc.
  • 22. Trinity Biotech PLC
  • 23. UCB S.A.
  • 24. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. AUTOIMMUNE DISEASE THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. AUTOIMMUNE DISEASE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. AUTOIMMUNE DISEASE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. AUTOIMMUNE DISEASE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AUTOIMMUNE DISEASE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ANTIHYPERGLYCEMICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY FUSION PROTEINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CYTOKINE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOMODULATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNOSUPPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY NONSTEROIDAL ANTI-INFLAMMATORY DRUGS (NSAIDS), BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PHOSPHODIESTERASE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY CORTICOSTEROIDS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY JAK INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INFLAMMATORY BOWEL DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY LUPUS ERYTHEMATOSUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY MULTIPLE SCLEROSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PSORIASIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RHEUMATOID ARTHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY TYPE 1 DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE PROGRESSION ALTERATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY IMMUNE SYSTEM MODULATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY PAIN MANAGEMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY REDUCTION OF INFLAMMATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 51. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 52. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 53. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 54. AMERICAS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 57. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 58. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 59. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 60. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 61. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 62. ARGENTINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 64. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 65. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 66. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 67. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 68. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 69. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. BRAZIL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 72. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 73. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 74. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 75. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 76. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 77. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 78. CANADA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 79. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 80. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 81. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 82. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 84. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 85. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 86. MEXICO AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 87. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 88. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 89. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 90. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 91. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 92. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 93. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 94. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED STATES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 106. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 108. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 110. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 111. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 112. AUSTRALIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 114. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 115. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 116. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 117. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 118. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 119. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. CHINA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 122. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 123. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 124. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 125. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 126. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 127. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 128. INDIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 129. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 130. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 131. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 132. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 133. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 134. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 135. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 136. INDONESIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 138. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 139. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 140. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 141. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 142. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 143. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. JAPAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 146. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 147. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 148. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 149. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 150. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 151. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 152. MALAYSIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 154. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 156. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 158. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 159. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 160. PHILIPPINES AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 162. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 163. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 164. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 165. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 166. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 167. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 168. SINGAPORE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 170. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 172. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 174. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 175. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 176. SOUTH KOREA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 177. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 178. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 179. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 180. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 182. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 183. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 184. TAIWAN AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 185. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 186. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 187. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 188. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 189. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 190. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 191. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 192. THAILAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 193. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 194. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 195. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 196. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 197. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 198. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 199. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 200. VIETNAM AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 210. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 211. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 212. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 213. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 214. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 215. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 216. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. DENMARK AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 219. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 220. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 221. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 222. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 223. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 224. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. EGYPT AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 226. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 227. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 228. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 229. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 230. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 231. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 232. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 233. FINLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 235. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 236. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 237. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 238. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 239. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 240. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. FRANCE AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 243. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 244. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 245. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 246. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 247. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 248. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. GERMANY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 250. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 251. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 252. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 253. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 254. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 255. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 256. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 257. ISRAEL AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 259. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 260. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 261. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 262. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 263. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 264. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. ITALY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 268. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 270. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 272. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. NETHERLANDS AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 274. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 275. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 276. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 277. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 278. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 279. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 280. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 281. NIGERIA AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 283. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 284. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 285. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 286. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 287. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 288. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 289. NORWAY AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 290. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 291. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 292. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 293. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 294. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
  • TABLE 295. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY INJECTABLE, 2018-2030 (USD MILLION)
  • TABLE 296. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. POLAND AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 298. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC TYPES, 2018-2030 (USD MILLION)
  • TABLE 299. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY BIOLOGICS, 2018-2030 (USD MILLION)
  • TABLE 300. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY SMALL MOLECULES, 2018-2030 (USD MILLION)
  • TABLE 301. QATAR AUTOIMMUNE DISEASE THERAPEUTICS MARKET SIZE, BY DISEA